# Adela

Source: https://onco.cc/companies/adela/  
OnCo record `adela` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adela, of Toronto, develops blood tests that profile methylation marks across all cell-free DNA fragments without sequencing the tumour itself, first to detect residual disease and immunotherapy response in advanced solid tumours and later to screen for multiple cancers with one test. The screening programme is still in study.

## Summary

Adela, headquartered in Toronto with US operations in Foster City, California, launched in June 2021 on technology from the Princess Margaret Cancer Centre and Sinai Health System. Its genome-wide methylome enrichment platform profiles all methylated cell-free DNA fragments in a blood sample without bisulphite conversion, enabling tissue-agnostic, tumour-naive tests that do not require sequencing the primary tumour. The lead application is minimal residual disease (MRD) and immunotherapy response monitoring in advanced solid tumours; a clinical validation of the tissue-free immunotherapy response test appeared in npj Precision Oncology in March 2026. A multi-cancer early detection (MCED) programme is in study, with progress shown at ASCO 2026. Adela raised a $60 million Series A in 2021 led by F-Prime Capital and $48 million in 2023 with Labcorp joining, $108 million in total.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Toronto
- Type: diagnostics
- Website: https://www.adelabio.com/

## Notes

- 2021 release dateline is Toronto and San Francisco; 2023 release dateline is Foster City, CA. Toronto chosen as HQ per the company origin. No specific cancer types are tagged because the tests are tissue-agnostic.

## Sources

- Official website: https://www.adelabio.com/
- Series A launch release (Jun 2021): https://www.adelabio.com/press/adela-debuts-with-60m
- $48 million financing (Sep 2023): https://www.adelabio.com/press/adela-announces-48-million-in-financing-and-leadership-addition-to-advance-tissue-agnostic-minimal-residual-disease-mrd-monitoring-product-portfolio-based-on-genome-wide-methylome-approach
- News page: https://www.adelabio.com/adela-news

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Deerfield Management](https://onco.cc/companies/deerfield-management/), [F-Prime Capital](https://onco.cc/companies/f-prime-capital/), [OrbiMed](https://onco.cc/companies/orbimed/), [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/adela.json